Regulatory Framework for Regenerative Medicine in India
Abstract
Regenerative medicine is a promising field of approach to repair or regenerate human cells, tissue or organs that have been damaged by trauma, disease, or congenital issues. Regenerative medicine is used when the body is incapable to heal itself. Stem cell and gene therapies are key components to Regenerative medicine, as they open the door to unique therapeutic applications. Stem cells are special human cells that are commonly found in different organs and tissues including the blood, brain, bone marrow, skin, muscle, heart, and liver tissues. These cells have the potential to develop into different types of cells such as skin cells, muscle cells, brain cells, and nerve cells. Regenerative medicine may improve your health and quality of life in the future with many new therapies for organ failure, Alzheimer’s, Parkinson’s, chronic heart diseases, dental injuries and so on. Over the past two decades, cell therapies and gene therapies have made increasing public attention. So, there is a need to form a clear regenerative medicine regulatory framework in India. In this article, it is presented with different applications, challenges and regulations of regenerative medicine in India.
Downloads
References
http://terpconnect.umd.edu/~jpfisher/index_files/L1.pdf
2. Bailey A, Mendicino M, Au P. An FDA perspective on preclinical development of cell-based regenerative medicine products. Nature Biotechnology [Internet]. 2014 [cited 10 December 2020];32(8):721-723. Available from:
https://pubmed.ncbi.nlm.nih.gov/25093890/
3. Mendelson A, Frenette P. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nature Medicine [Internet]. 2014 [cited 2020 Dec 13];20(8):833-846. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459580/
4. Bajaj P, Schweller R, Khademhosseini A, West J, Bashir R. 3D Biofabrication Strategies for Tissue Engineering and Regenerative Medicine. Annual Review of Biomedical Engineering [Internet]. 2014 [cited 2021 Jan 04];16(1):247-276. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131759/
5. Patrick Baert A. That 'CRISPR Babies' Scientist Was Just Sentenced to Jail in China [Internet]. ScienceAlert. 2019 [cited 2021 Jan 10]. Available from:
https://www.sciencealert.com/chinese-scientist-has-been-sentenced-to-three-years-jail-for-gene-editing-babies
6. National Guidelines for Gene Therapy Product Development and Clinical Trials [Internet]. 2021 [cited 2021 Jan 14]. Available from:
https://www.nhp.gov.in/NHPfiles/guidelines_GTP.pdf
7. National Guidelines for Stem Cell Research [Internet]. Dbtindia.gov.in. 2021 [cited 2021 Jan 16]. Available from:
http://www.dbtindia.gov.in/sites/default/files/National_Guidelines_StemCellResearch-2017.pdf
8. Sivandzade F, Cucullo L. Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview. International Journal of Molecular Sciences [Internet]. 2021 [cited 2021 Jan 22];22(4):2153. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926761/
9. Regenerative medicine - Wikipedia [Internet]. En.wikipedia.org. 2021 [cited 2021 Jan 26]. Available from:
https://en.wikipedia.org/wiki/Regenerative_medicine
10. Yamada Y, Nakamura-Yamada S, Konoki R, Baba S. Promising advances in clinical trials of dental tissue-derived cell-based regenerative medicine. Stem Cell Research & Therapy [Internet]. 2020 [cited 2021 Jan 27];11(1). Available from:
https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01683-x
11. Nasser M, Qi X, Zhu S, He Y, Zhao M, Guo H et al. Current situation and future of stem cells in cardiovascular medicine. Biomedicine & Pharmacotherapy [Internet]. 2020 [cited 2021 Feb 03];132:110813. Available from:
https://reader.elsevier.com/reader/sd/pii/S0753332220310064?token=B420858EDAF9F48D9D31C85BA04DD03F3CEB278C42F6FC5EF2CC54FCFC859148A1AEE87829D02CBB83D18358FF72FEBD&originRegion=eu-west-1&originCreation=20210630111844
12. Dessie G, Derbew Molla M, Shibabaw T, Ayelign B. Role of Stem-Cell Transplantation in Leukemia Treatment. Stem Cells Cloning [Internet]. 2020 [cited 2021 Feb 04];132:110813. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493021/
13. Pan G, Mu Y, Hou L, Liu J. Examining the therapeutic potential of various stem cell sources for differentiation into insulin-producing cells to treat diabetes. Annales d' Endocrinologie [Internet]. 2019 [cited 2021 Feb 08];80(1):47-53. Available from:
https://www.sciencedirect.com/science/article/pii/S0003426618311788?via%3Dihub
14. Lahiry S, Choudhury S, Sinha R, Chatterjee S. The National Guidelines for Stem Cell Research (2017): What academicians need to know?. Perspectives in Clinical Research [Internet]. 2019 [cited 2021 Mar 06];10(4):148. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801994/
15. Qiu T, Hanna E, Dabbous M, Borislav B, Toumi M. Regenerative medicine regulatory policies: A systematic review and international comparison. Health Policy [Internet]. 2020 [cited 2021 Mar 12];124(7):701-713. Available from:
https://pubmed.ncbi.nlm.nih.gov/32499078/
16. Beumer K, Bhattacharya S. Emerging technologies in India: Developments, debates and silences about nanotechnology. Science and Public Policy [Internet]. 2013 [cited 2021 Mar 24];40(5):628-643. Available from:
https://academic.oup.com/spp/article/40/5/628/1676774
17. Guidelines and Best Practices for Safe Handling of Nanomaterials in Research Laboratories and Industries [Internet]. Dst.gov.in; 2021 [cited 2021 Apr 03]. Available from:
https://dst.gov.in/sites/default/files/Draft-Guidelines%20.pdf
18. Draft Guidelines for Safe Handling of Nanomaterials [Internet]. Economic and Political Weekly. 2021 [cited 2021 Apr 25]. Available from:
https://www.epw.in/journal/2016/23/commentary/draft-guidelines-safe-handling-nanomaterials.html
19. Beumer K. Travelling risks: How did nanotechnology become a risk in India and South Africa?. Journal of Risk Research [Internet]. 2017 [cited 2021 Apr 29];21(11):1362-1383. Available from:
https://pure.rug.nl/ws/portalfiles/portal/76825405/Travelling_risks_How_did_nanotechnology_become_a_risk_in_India_and_South_Africa.pdf
20. LI P, FAULKNER A. 3D Bioprinting Regulations: a UK/EU Perspective. European Journal of Risk Regulation [Internet]. 2017 [cited 2021 May 04];8(2):441-447. Available from:
https://www.cambridge.org/core/journals/european-journal-of-risk-regulation/article/3d-bioprinting-regulations-a-ukeu-perspective/ADC91ED03B04BDA7FBDF06BBCE5CD2B2
21. Taur Y, Xavier J, Lipuma L, Ubeda C, Goldberg J, Gobourne A et al. Intestinal Domination and the Risk of Bacteremia in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases [Internet]. 2012 [cited 2021 May 07];55(7):905-914. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657523/
22. Laxminarayan R, Chaudhury R. Antibiotic Resistance in India: Drivers and Opportunities for Action. PLOS Medicine [Internet]. 2016 [cited 2021 May 12];13(3):e1001974. Available from:
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001974
23. Alliance for Regenerative Medicine. 2021 [cited 2021 May 22]. Available from:
https://alliancerm.org/available-products/
24. Regenerative medicines market value worldwide by therapy type 2016-2025 | Statista [Internet]. Statista. 2021 [cited 2021 Jun 25]. Available from:
https://www.statista.com/statistics/871252/regenerative-medicines-market-value-worldwide-by-therapy-type/
25. Ongoing clinical trials for regenerative medicine by phase 2020 | Statista [Internet]. Statista. 2021 [cited 2021 Jun 30]. Available from:
https://www.statista.com/statistics/1088694/regenerative-medicine-clinical-trials-by-phase-and-therapy/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
